Janney Montgomery Scott LLC Acquires 2,130 Shares of Illumina, Inc. (NASDAQ:ILMN)

Janney Montgomery Scott LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 32.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,710 shares of the life sciences company’s stock after buying an additional 2,130 shares during the period. Janney Montgomery Scott LLC’s holdings in Illumina were worth $1,164,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Planning raised its position in Illumina by 3.4% in the 2nd quarter. Creative Planning now owns 16,144 shares of the life sciences company’s stock worth $1,685,000 after purchasing an additional 525 shares during the period. Cetera Investment Advisers grew its holdings in Illumina by 25.8% in the second quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after purchasing an additional 3,767 shares during the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Illumina in the 2nd quarter valued at approximately $2,331,000. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Illumina by 403.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 14,626 shares of the life sciences company’s stock valued at $1,527,000 after purchasing an additional 11,718 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Illumina by 6.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 76,280 shares of the life sciences company’s stock valued at $9,948,000 after acquiring an additional 4,558 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ILMN. Piper Sandler dropped their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Royal Bank of Canada boosted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. UBS Group raised their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen boosted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $164.84.

Illumina Stock Performance

NASDAQ ILMN opened at $124.20 on Wednesday. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business has a 50 day moving average price of $138.57 and a 200 day moving average price of $135.43. The company has a market capitalization of $19.70 billion, a P/E ratio of -12.47 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.